Table 2.
Clinicopathologic Features of Patients With Breast Implant–Associated Anaplastic Large-Cell Lymphoma
| Clinical Feature | Patients With BI-ALCL |
|---|---|
| Age, years | |
| Median | 54 |
| Range | 28-87 |
| Laterality | |
| Right | 46 (52.9) |
| Left | 37 (42.5) |
| Bilateral | 4 (4.6) |
| Reason for initial implantation | |
| Cosmetic | 51 (58.6) |
| Breast cancer reconstruction | 36 (41.4) |
| Type of implant (n = 81) | |
| Silicone | 40 (49.4) |
| Saline | 41 (50.6) |
| Texture of implant (n = 48) | |
| Purely textured | 45 (93.7) |
| Purely smooth | 0 (0) |
| Both smooth/textured | 3 (2.3) |
| Interval to lymphoma diagnosis, years | |
| Median | 8 |
| Mean | 9.1 |
| Range | 2-25 |
| Clinical presentation | |
| Effusion only | 52 (59.8) |
| Mass only | 15 (17.2) |
| Effusion and mass | 17 (19.5) |
| No mass, no effusion | 3 (3.4) |
| T stage | |
| T1 | 31 (35.6) |
| T2 | 11 (12.6) |
| T3 | 14 (16.1) |
| T4 | 30 (34.5) |
| N stage | |
| 0 | 74 (85.1) |
| 1 | 13 (14.9) |
| Ann Arbor stage at presentation | |
| IE | 74 (86.2) |
| IIE | 13 (13.8) |
| TNM stage at presentation | |
| IA | 31 (35.6) |
| IB | 10 (11.5) |
| IC | 12 (13.8) |
| IIA | 22 (25.3) |
| IIB | 4 (4.6) |
| III | 8 (9.2) |
| IV | 0 (0) |
| Chemotherapy (n = 51) | |
| CHOP | 44 (86.3) |
| 3 cycles | 11 |
| 4 cycles | 2 |
| 6 cycles | 28 |
| NA | 3 |
| CHOEP | 11 (21.6) |
| 6 cycles | 11 |
| NS | 2 (3.9) |
| ABVD | 2 (3.9) |
| Hyper-CVAD | 1 (1.9) |
| Follow-up, months | |
| Median | 30 |
| Mean | 45 |
| Range | 3-217 |
NOTE. Data are given as No. (%) unless otherwise noted.
Abbreviations: ABVD, adriamycin, bleomycin, vinblastine, and dacarbazine; BI-ALCL, breast implant–associated anaplastic large-cell lymphoma; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CHOEP, CHOP plus etoposide; Hyper-CVAD course A, hyperfractionated; cyclophosphamide, vincristine, doxorubicin, and dexamethasone with course B: methotrexate and cytarabine; NA, not available; NS, chemotherapy not specified.